Quinolinic acid in the pathogenesis of Alzheimer's disease
- PMID: 15206729
- DOI: 10.1007/978-1-4615-0135-0_19
Quinolinic acid in the pathogenesis of Alzheimer's disease
Abstract
We propose that the tryptophan catabolites produced through the kynurenine pathway (KP), and more particularly quinolinic acid (QUIN), may play an important role in the pathogenesis of Alzheimer's disease (AD). In this study, we demonstrated that after 72 hours amyloid peptide (Abeta) 1-42 induced indoleamine 2,3-dioxygenase (IDO) expression and in a significant increase in production of QUIN by human macrophages and microglia. In contrast, Abeta11-40 and Prion peptide (PrP) 106-126 did not induce any significant increase in QUIN production. We also investigated the potential modulatory effect of QUIN and kynurenic acid (KYNA) on Abeta11-42 and Abeta1-40 aggregation. After 24 and 120 hours, we did not observe any significant difference in the level of aggregation compared to the control (Abeta alone). Abeta has been shown to induce IL1-beta mRNA expression by human foetal astrocytes and macrophages. We demonstrate that QUIN has the same effect. Interestingly, IL-1beta has been found in association with plaques in AD. All together these data imply that QUIN may be, locally, one of the factors involved in the pathogenesis of neuronal damage in AD.
Similar articles
-
A beta 1-42 induces production of quinolinic acid by human macrophages and microglia.Neuroreport. 2003 Dec 19;14(18):2311-5. doi: 10.1097/00001756-200312190-00005. Neuroreport. 2003. PMID: 14663182
-
Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons.Glia. 2005 Jan 1;49(1):15-23. doi: 10.1002/glia.20090. Glia. 2005. PMID: 15390107
-
Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus.Neuropathol Appl Neurobiol. 2005 Aug;31(4):395-404. doi: 10.1111/j.1365-2990.2005.00655.x. Neuropathol Appl Neurobiol. 2005. PMID: 16008823
-
Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease.Redox Rep. 2002;7(4):199-206. doi: 10.1179/135100002125000550. Redox Rep. 2002. PMID: 12396664 Review.
-
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.J Neurol Sci. 2012 Dec 15;323(1-2):1-8. doi: 10.1016/j.jns.2012.08.005. Epub 2012 Aug 29. J Neurol Sci. 2012. PMID: 22939820 Review.
Cited by
-
Kynurenine Pathway in Skin Cells: Implications for UV-Induced Skin Damage.Int J Tryptophan Res. 2012;5:15-25. doi: 10.4137/IJTR.S9835. Epub 2012 Jul 3. Int J Tryptophan Res. 2012. PMID: 22837645 Free PMC article.
-
Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity.J Geriatr Care Res. 2018;5(2):57-67. J Geriatr Care Res. 2018. PMID: 30984874 Free PMC article.
-
Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.Arch Biochem Biophys. 2021 Jan 15;697:108702. doi: 10.1016/j.abb.2020.108702. Epub 2020 Dec 1. Arch Biochem Biophys. 2021. PMID: 33275878 Free PMC article. Review.
-
Immunosuppressive Amino-Acid Catabolizing Enzymes in Multiple Sclerosis.Front Immunol. 2021 Jan 20;11:600428. doi: 10.3389/fimmu.2020.600428. eCollection 2020. Front Immunol. 2021. PMID: 33552055 Free PMC article. Review.
-
Evidence for a dual role of an active site histidine in α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase.Biochemistry. 2012 Jul 24;51(29):5811-21. doi: 10.1021/bi300635b. Epub 2012 Jul 12. Biochemistry. 2012. PMID: 22746257 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials